NTX1088 First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
- Coordinator
- Nectin Therapeutics Ltd, Israel
- Runs
- 1 August 2024 to 31 January 2028
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101164808
What the project is doing
In the project's own words, from its summary on CORDIS.
Nectin Therapeutics (NectinTx) is a venture-backed company with a top-notch team focused on innovative therapeutic options for cancer patients. To address the limitations of available therapies, the company has developed a diverse pipeline of antibodies that overcome immune inhibitory pathways deployed by the tumours. NTX1088 is a monoclonal antibody that binds human poliovirus receptor (PVR) and activates patient’s immune system to fight cancer through a triple mechanism of action never demonstrated before.
A comprehensive preclinical dataset was generated to show the robust antitumor activity of NTX1088 in vitro and in vivo. Following IND approval and strong backing from key opinion leaders, Phase I clinical trial has commenced, aimed to enrol patients with solid tumours. The project will accelerate the clinical development of NTX1088 towards a novel therapy on the €80 billion immune-oncology drug market, resulting in better outcomes for patients and reduced societal and economic burden associated with cancer.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Nectin Therapeutics Ltd | Jerusalem | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI